The apheresis industry market involves the medical technology and healthcare sector focused on systems, devices, and disposable kits used to separate blood components—such as plasma, platelets, red blood cells, and white blood cells—from a donor or patient. It spans donor apheresis for blood component collection and transfusion medicine, as well as therapeutic apheresis for treating chronic, autoimmune, hematological, and neurological disorders.
The global apheresis market is projected to reach USD 4.41 billion by 2031 from USD 3.02 billion in 2026, growing at a compound annual growth rate (CAGR) of 7.9%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950
The apheresis industry market is primarily driven by the rising global prevalence of chronic, autoimmune, neurological, and hematological disorders that require blood component therapy, alongside an increasing demand for plasma-derived biologics and advancements in automated blood separation technologies. However, market expansion is heavily restrained by the high procedural and operational costs of advanced devices and disposable kits, stringent regulatory requirements for plasma collection, and limited healthcare infrastructure or blood donation networks in developing nations. Lucrative opportunities exist in the rising adoption of apheresis for cell and gene therapy workflows (such as CAR-T cell collection), expanding blood bank infrastructure, and the strategic integration of AI and automation to adjust treatment parameters for personalized medicine. Despite these prospects, the market faces key challenges, including a severe shortage of specialized healthcare professionals, high risks of procedure-related adverse events or donor safety concerns like citrate toxicity, and competition from alternative medical therapies.
The target customers for the apheresis industry market primarily encompass institutional buyers, including hospitals, academic medical centers, blood collection centers, blood banks, dialysis centers, and specialty clinics like oncology or neurology units. These customers need advanced, safe, and highly efficient systems to support therapeutic applications for chronic illnesses—such as autoimmune, hematological, neurological, and renal diseases—as well as donor management for extracting high-quality plasma and specific blood components. They show a strong preference for automation, data analytics integration with electronic health records (EHR), and a major shift toward automated, disposable apheresis kits to lower operational risks and optimize patient care. Their purchasing behavior is heavily institutional, driven by long-term strategic contracts, regular replenishment cycles for high-volume consumables, strict regulatory compliance certifications, and evidence-based clinical efficacy to justify large capital equipment outlays.
Market entry, expansion, and profitability in the apheresis industry market are heavily shaped by stringent regulatory frameworks, continuous technological innovations, and distinct economic pressures. Regulators enforce rigorous safety, quality assurance, and clinical validation standards for device approvals, while local reimbursement frameworks and policies—such as the 18% CMS rate cut for hospital outpatient plasma exchange in 2025—can narrow profit margins and restrain new equipment orders. Technologically, the market is disrupted by automated blood component separation systems, real-time wireless monitoring, and the surging adoption of apheresis collections in regenerative medicine for CAR T-cell and gene therapies, which significantly improve patient throughput and clinical outcomes. However, substantial economic barriers persist, including high upfront capital costs for automated devices ranging from USD 85,000 to USD 140,000, high ongoing expenditures for sterile disposable kits, and limited healthcare infrastructure in cost-sensitive, developing regions that together restrict widespread market penetration and institutional profitability.
The apheresis industry market is being significantly shaped by a rapid shift toward automated, software-driven platforms integrated with single-use disposable kits to improve efficiency, cell yields, and safety across both donor and therapeutic procedures. A major emerging trend is the convergence of apheresis suites into core oncology infrastructure, driven by the expansion of cellular therapies like CAR-T where standardized leukapheresis serves as a recurring pharmaceutical input, alongside a growing procurement preference for eco-friendly consumables that reduce water and energy consumption. These trends are evolving swiftly to meet rising global demand for plasma-protein therapeutics and automated component collection, as highlighted by robust growth indicators including projected compound annual growth rates (CAGRs) of 7.24% for disposables and consumables through 2031, a notable 8.35% CAGR for photopheresis applications, and blood banks expanding at an 8.68% CAGR from 2026 to 2031.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950
Technological innovations disrupting the apheresis industry are centered on automation, software-driven platforms, and enhanced personalization. Key advancements gaining significant traction include the integration of artificial intelligence and machine learning to enable real-time monitoring and personalized treatment adjustments. Furthermore, the industry is seeing a major shift toward selective apheresis techniques, such as plasma adsorption and double filtration plasma absorption, which allow for the precise removal of specific disease-causing factors. The market is also being disrupted by the development of portable and point-of-care apheresis devices that improve accessibility in home healthcare and ambulatory settings, alongside emerging microfluidics and advanced materials engineering designed to optimize cell separation and reduce cell damage.
In the apheresis industry market, short-term trends are characterized by tactical hospital procurement shifts, temporary vendor-financed leasing models, and episodic purchasing fluctuations driven by sudden CMS reimbursement rate cuts. Conversely, long-term structural shifts are firmly anchored in permanent medical-grade infrastructure and oncological advancements. These enduring transformations include the integration of automated, software-driven apheresis platforms and the widespread adoption of single-use disposable kits to satisfy strict hospital hygiene protocols. Furthermore, the market is undergoing a permanent evolution due to the rising global demand for source plasma to produce plasma-derived products, alongside the institutionalization of apheresis suites as core oncology infrastructure to support FDA-approved CAR-T cell therapies.
Source:https://www.marketsandmarkets.com/Market-Reports/apheresis-market-950.html
